These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 303860)

  • 21. [Dyskinetic syndromes in psychiatric patients (author's transl)].
    Lutrand JC; Ducamin JP
    Sem Hop; 1978 Dec 18-25; 54(45-46):1465-8. PubMed ID: 34882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal disorders in hyperkinetic movement disorders and ataxia.
    Pradeep S; Mehanna R
    Parkinsonism Relat Disord; 2021 Sep; 90():125-133. PubMed ID: 34544654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen treatment of dyskinetic disorders.
    Koller WC; Barr A; Biary N
    Neurology; 1982 May; 32(5):547-9. PubMed ID: 7200210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deep brain stimulation for the treatment of hyperkinetic movement disorders.
    di Biase L; Munhoz RP
    Expert Rev Neurother; 2016 Sep; 16(9):1067-78. PubMed ID: 27254274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders.
    Mondrup K; Dupont E; Braendgaard H
    Acta Neurol Scand; 1985 Sep; 72(3):341-3. PubMed ID: 3864333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Adv Neurol; 1983; 37():277-89. PubMed ID: 6574695
    [No Abstract]   [Full Text] [Related]  

  • 28. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
    Growdon JH; Young RR; Shahani BT
    Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Idiopathic (Oral) and Tardive Dyskinesia: Pathogenesis, Epidemiology, and Treatment].
    Mukai Y
    Brain Nerve; 2023 Jan; 75(1):23-35. PubMed ID: 36574970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Movement disorders and stroke.
    Defebvre L; Krystkowiak P
    Rev Neurol (Paris); 2016; 172(8-9):483-487. PubMed ID: 27476417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
    Anders TF; Cann HM; Ciaranello RD; Barchas JD; Berger PA
    Neuropadiatrie; 1978 May; 9(2):157-66. PubMed ID: 308621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
    Jankovic J; Beach J
    Neurology; 1997 Feb; 48(2):358-62. PubMed ID: 9040721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced and tardive movement disorders.
    Vernon GM
    J Neurosci Nurs; 1991 Jun; 23(3):183-7. PubMed ID: 1831484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Trazodone in involuntary pathologic movements].
    Rubino R; Provera P; Gilardengo P; Penza MT
    Riv Neurol; 1984; 54(1):52-73. PubMed ID: 6718959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
    Bédard P; Parkes JD; Marsden CD
    Br Med J; 1978 Apr; 1(6118):954-6. PubMed ID: 638546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes.
    Fog R; Pakkenberg H
    Acta Neurol Scand; 1970; 46(2):249-51. PubMed ID: 4246984
    [No Abstract]   [Full Text] [Related]  

  • 39. Current concepts in the management of movement disorders.
    Olanow CW
    Clin Neurosurg; 1981; 28():137-70. PubMed ID: 6119175
    [No Abstract]   [Full Text] [Related]  

  • 40. Improvement of action myoclonus by an administration of 5-hydroxytryptophan and carbidopa in a child with muscular subsarcolemmal hyperactivity.
    Nakano K; Hayakawa T; Shishikura K; Ohsawa M; Suzuki H; Fukuyama Y
    Brain Dev; 1990; 12(5):516-20. PubMed ID: 2288384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.